Cargando…
1027. Long-Term Efficacy, Safety, and Durability of Ibalizumab-Based Regimens in Subgroup of TMB-202 Participants
BACKGROUND: Third line antiretroviral regimens have been associated with suboptimal virologic suppression, due to drug cross-resistance and regimen complexity. Yet, in treatment-experienced (TE) HIV patients, ART durability is essential for preventing further resistance and decreasing HIV-associated...
Autores principales: | Towner, William, DeJesus, Edwin, Schrader, Shannon, De Vente, Jerome, McGary, Colleen, Zogheib, Mohammed, Weinheimer, Steven, Mesquita, Pedro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776877/ http://dx.doi.org/10.1093/ofid/ofaa439.1213 |
Ejemplares similares
-
661. Ibalizumab Efficacy and Safety Through 48 Weeks of Treatment: Results of an Expanded Access Protocol (TMB-311)
por: Emu, Brinda, et al.
Publicado: (2019) -
1008. Disease Severity Impact on Long-Term Virologic Response to Ibalizumab in Expanded Access Protocol (TMB-311)
por: Kumar, Princy, et al.
Publicado: (2020) -
544. Pharmacokinetic Profile of Ibalizumab From a Phase 3 Trial
por: Kumar, Princy N, et al.
Publicado: (2018) -
Forty-eight-Week Safety and Efficacy On-Treatment Analysis of Ibalizumab in Patients with Multi-Drug Resistant HIV-1
por: Emu, Brinda, et al.
Publicado: (2017) -
Ibalizumab: First Global Approval
por: Markham, Anthony
Publicado: (2018)